Cancer name Lymphoma
Cancer Type DLBC
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment si-A20
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Cell
Signature CD8+ IFN-γ+ T cells
Official Symbol Exhausted CD8+ T cell
Mode of action CE_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description Moreover, mice treated with si-A20 and si-A20′ showed a significant increase in CD4+IFN-γ+ and CD8+IFN-γ+ T cells compared with that in control groups, which indicated that the increase in cytotoxic T lymphocytes (CTL) might also contribute to tumor regression.
PMID 26561336
Title Inhibition of A20 expression in tumor microenvironment exerts anti-tumor effect through inducing myeloid-derived suppressor cells apoptosis.